Cordlife reported FY2025 revenue of SGD 38.9 million, up 40.5%, and a net loss of SGD 12.6 million, compared with a net loss of SGD 18.9 million a year earlier. Gross profit for FY2025 rose 94.2% to SGD 22.4 million, with gross profit margin at 57.7% and net loss margin at -32.5%. Loss before tax for FY2025 was SGD 11.0 million. For Q4FY2025, Cordlife posted revenue of SGD 9.5 million, up 13.5%, and a net loss of SGD 5.6 million. Q4 gross profit increased 29.8% to SGD 5.4 million, with gross profit margin at 57.2%. The company said FY2025 performance reflected the full resumption of Singapore operations between 14 January 2025 and 29 September 2025, improved performance in Hong Kong and Malaysia, and reduced revenue reversal related to refunds. Following the voluntary cessation of new sample collections in Singapore from 30 September 2025, Cordlife said Q4 revenue was derived mainly from recurring storage and related services. Cordlife added that Singapore’s cord blood banking service licence was renewed for one year and its human tissue banking service licence for two years from 14 January 2026, with modified licence conditions, and noted Indonesia’s facility was re-accredited by AABB for the fourth consecutive time in Q4FY2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cordlife Group Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: WRHVYO5O20W0FCAB) on February 27, 2026, and is solely responsible for the information contained therein.